title: Complete pain relief after bevacizumab in a patient with neurofibromatosis type 2.
authors.affiliation: Department of Medical Oncology, University Hospital of Bern , Switzerland.
authors.forename: Attila
authors.initials: A
authors.lastname: Kollár
authors.forename: Ekkehard
authors.initials: E
authors.lastname: Hewer
authors.forename: Frauke
authors.initials: F
authors.lastname: Kellner-Weldon
authors.forename: Adrian
authors.initials: A
authors.lastname: Ochsenbein
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008161:Lumbosacral Region; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy*; D016518:Neurofibromatosis 2 / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab